Dr. Edenfield is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 W Faris Rd
Greenville, SC 29605Phone+1 864-679-3900Fax+1 864-679-3901
Education & Training
- National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1995 - 1998
- National Capital ConsortiumResidency, Internal Medicine, 1992 - 1995
- University of Miami Leonard M. Miller School of MedicineClass of 1992
Certifications & Licensure
- SC State Medical License 2003 - 2025
- FL State Medical License 1994 - 2005
- NC State Medical License 1999 - 2004
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Clinical Trials
- A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
- Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
- Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsTrilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer:...Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García-Campelo, William Jeffery Edenfield
Cancer Medicine. 2021-09-01 - 74 citationsParsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William Jeffery Edenfield
Blood. 2019-04-18 - 18 citationsBMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a...John Hilton, Mihaela Cristea, Sophie Postel-Vinay, Capucine Baldini, Mark Voskoboynik
Cancers. 2022-08-23
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: